Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Roche .
Filed returns
9
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2026 | Roche | Health | Revisions to the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) legislative frameworks in the context of Ireland’s H2 2026 Presidency of the Council of the European Union. (Legislation) | 5 | On lobbying.ie |
| May–Aug 2026 | Roche | Economic Development and Industry | Progression and refinement of legislative proposals within the EU Biotech Act during Ireland’s H2 2026 Presidency of the Council of the European Union. (Public policy or programme) | 5 | On lobbying.ie |
| May–Aug 2026 | Roche | Economic Development and Industry | Quantitative target-setting and governance structures for Ireland’s National Life Science Strategy. (Public policy or programme) | 9 | On lobbying.ie |
| Sep–Dec 2025 | Roche | Health | The development of a National Life Science Strategy should embrace international best practices through a coordinated, cross-departmental approach (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2025 | Roche | Health | Reform of national pricing and reimbursement systems for new medicines and sustainable increased investment in innovative medicines (Public policy or programme) | 6 | On lobbying.ie |
| Sep–Dec 2024 | Roche | Health | Patient access to new medicines (Public policy or programme) | 4 | On lobbying.ie |
| Sep–Dec 2021 | Roche | Health | Request to consider issuing a temporary authorisation of a medicinal product (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2017 | Roche | Health | Drug Reimbursement (Public policy or programme) | 24 | On lobbying.ie |
| Jan–Apr 2017 | Roche | Health | Drug Reimbursement (Public policy or programme) | 1 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 7 | 77.8% | |
| Economic Development and Industry | 2 | 22.2% |